以Toll样受体为靶点的药物研究进展  

Progress in drugs targeting to Toll-like receptors

作　　者：张志强[1] 余聂芳[1] 

机构地区：[1]中南大学药学院,长沙410013

出　　处：《中南药学》2014年第5期457-463,共7页Central South Pharmacy

基　　金：国家自然科学基金项目(No.30873137;No.30772645;No.81172927)

摘　　要：Toll样受体是一种保守的模式识别受体,能识别病原相关分子模式(PAMP)和损伤相关分子模式(DAMP),TLRs通过多种信号传递调控免疫系统功能,活化NF-κB信号通路,调节TNF-α、IL-6和IFN-α等多种细胞因子的分泌,从而调节或控制天然免疫与获得性免疫。研究发现,TLRs在自身免疫性疾病、肿瘤等疾病的发生发展过程中起着重要的作用。因此,TLRs正成为重要的药物发现靶点,以TLRs为药物靶点设计的化合物已上市或进入临床研究阶段。本文总结了以TLRs为靶点的药物研究进展。Toll-like receptors （TLRs） are a family of evolutionally conserved pattern recognition receptors that detect and clear pathogen-associated molecular pattern and damage-associated molecular pattern. TLRs improve the immune system through a variety of signal transductions, activate NF-KB signaling pathway and regulate the secretion of cytokines such as TNF-α, IL-6 and IFN-a, and ultimately modulate the function of immunity system. TLRs play an important role in auto- immune diseases, cancer and other diseases developmental process. TLRs are important drug discovery targets. Recently, many agents targeting TLRs are entering clinical studies. This paper summarizes TLRs as a target in drug research.

关 键 词：TOLL样受体 信号通路 药物靶点 免疫治疗 

分 类 号：R966[医药卫生—药理学]